LC-MS characterization of valsartan degradation products and comparison with LC-PDA by Pires, Sumaia Araújo et al.
*Correspondence: M. G. Trevisan. Laboratório de Análise e Caracterização 
de Fármacos - LACFar. Instituto de Química. Universidade Federal de Alfenas. 
37130-000 - Alfenas - MG, Brasil. E-mail: trevisan@unifal-mg.edu.br
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 51, n. 4, oct./dec., 2015
http://dx.doi.org/10.1590/S1984-82502015000400010
LC-MS characterization of valsartan degradation products and 
comparison with LC-PDA
Sumaia Araújo Pires1, Letícia Martins Mota1, Jerusa Simone Garcia1, Phellipe Honorio Amaral2, 
Eduardo César Meurer2, Marcos Nogueira Eberlin2, Marcello Garcia Trevisan1,*
1Laboratory of Pharmaceutical Analysis and Characterization, LACFar, Institute of Chemistry, Federal University of Alfenas, 
Alfenas, MG, Brazil, 2Thomson Laboratory of Mass Spectrometry, Institute of Chemistry, UNICAMP, Campinas, SP, Brazil
Valsartan was submitted to forced degradation under acid hydrolysis condition as prescribed by the 
ICH. Degraded sample aliquots were separated via HPLC using a Hypersil ODS (C18) column (250 
x 4.6 mm i.d., 5 µm). Either photodiode array (PDA) detection or mass spectrometry (MS) full scan 
monitoring of HPLC runs were used. HPLC-PDA failed to indicate Valsartan degradation under forced 
acid degradation, showing an insignificant peak area variation and that Valsartan apparently remained 
pure. HPLC-MS using electrospray ionization (ESI) and total ionic current (TIC) monitoring did not 
reveal any peak variation either, but inspection of the ESI mass spectra showed the appearance of 
m/z 306 and m/z 352 ions for the same retention time as that of Valsartan (m/z 436). These ions were 
identified as being protonated molecules of two co-eluting degradation products formed by hydrolysis. 
These assignments were confirmed by ESI-MS/MS with direct infusion of the degraded samples. The 
results showed that the use of selective HPLC-MS is essential for monitoring Valsartan degradation. 
Efficient HPLC separation coupled to selective and structural diagnostic MS monitoring seems therefore 
mandatory for comprehensive drug degradation studies, particularly for new drugs and formulations, 
and for method development.
Uniterms: Valsartan. Stress testing. Degradation products. Stability-indicating. Acidic hydrolysis.
Valsartana (VAL) foi submetida à degradação forçada em meio ácido conforme procedimento descrito 
no ICH. Os produtos de degradação (PDs) foram monitorados ao longo do tempo de degradação pela 
técnica de Cromatografia Líquida (LC) utilizando uma coluna Hypersil ODS (C18) (250 x 4,6 mm d.i., 
5 µm). A detecção foi feita com dois detectores: espectrofotométrico (PDA) e espectrometria de massas 
(MS) por corrente iônica total. Ambas as técnicas falharam na identificação dos PDs obtidos ao longo do 
monitoramento, mostrando insignificantes variações na área do pico e permanecendo com pureza de pico 
ao longo de toda a eluição. Somente depois da avaliação por íon extraído (XIC), foi possível observar o 
aumento do íon m/z 306 e m/z 352 exatamente no mesmo tempo de retenção do íon molecular (m/z 436). 
Estes resultados mostram um caso simples e didático em que somente o uso de um método seletivo de 
LC-MS pode ser utilizado para monitorar produtos de degradação. Neste trabalho, é apresentado um caso 
real em que a separação por LC deve ser acoplada a métodos seletivos obtidos por MS, especialmente 
no estudo de PDs para novos fármacos, formulações e no desenvolvimento de métodos.
Unitermos: Valsartana. Teste de estresse. Produtos de degradação. Indicativo de estabilidade. Hidrólise 
ácida.
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INTRODUCTION
The identification of drug degradation products 
plays a crucial role in drug discovery and development 
(Alsante et al., 2003). Understanding drug degradation 
pathways affords information that is critical for drug 
safety and potency assessment, since very fast degradation 
and harmful degradation products may deactivate active 
molecules. The parent ICH stability testing guideline 
(ICH, 2003) and the Brazilian Health Surveillance Agency 
(ANVISA) (Brasil, 2013) require that drugs be subjected 
to a series of stress degradation studies, followed by proper 
characterization of the degradation products (DP).
Degradation studies via stress testing simulate the 
most likely environments that the drug may be subjected 
to from production to storage. These stress tests are 
important for inference of the degradation routes of 
pharmaceutical compounds and inform molecule stability 
across different stress conditions. The ICH guidelines 
(ICH, 2003) were conceived for the characterization of the 
inherent stability of a particular product, determination of 
possible DP, validation of the ability of analytical methods 
to evaluate the chemical stability of products and finally 
the quantification of the total and individual impurities 
present in formulations.
DP are normally associated with storage, but 
may also be formed during formulation dosage and/or 
processing under the influence of temperature, humidity, 
and light (Liu et al., 2011a). HPLC-PDA and HPLC-
UV are the primary stability-indicating methods used to 
monitor impurities/DP during stress testing and storage 
(Alsante et al., 2003). Although these techniques seem 
efficient for a variety of degradation studies (Thomas et 
al., 2012; Sharma et al., 2011; Bansal et al., 2008), they 
may fail to detect products lacking a chromophore group 
(Bansal et al., 2008) or with co-eluting sets of degradation 
products which may even co-elute with the parent drug and 
lead to false stability results.
HPLC-UV and HPLC-PAD are two largely used 
stability-indicating methods, but Liquid Chromatography 
Coupled to Mass Spectrometry (LC-MS) has become the 
gold standard technique in drug degradation monitoring 
due to its high DP sensitivity and selectivity as a result of 
the detailed structural information it provides (Zhang and 
Pramanik, 2010; Jocic et al., 2009; Bhardwaj, Singh, 2008; 
Liu et al., 2011b; Pan et al., 2011). At present, direct MS 
analysis approaches using soft ionization methods applied 
to drug pills have been reported and may also be suitable 
for some drugs (Amaral et al., 2011).
Valsartan (VAL) is a potent and highly selective 
oral drug largely used for the treatment of hypertension 
due to its effect as an active antagonist at the angiotensin 
II AT1-receptor (Krishanaiah et al., 2010) and because 
its solid-state characterization and compatibility have 
been established (Julio et al., 2013). In the present study, 
we report on false Valsartan stability results observed 
in a degradation study under acid stress condition using 
HPLC-PDA and the actual instability obtained by HPLC-
MS monitoring.
MATERIAL AND METHODS
Samples and reagents
Valsartan (VAL) was supplied by Dr. Reddys, 
India (batch AFEH002828) and used without further 
purification. MS grade Acetonitrile (ACN) from Sigma-
Aldrich (São Paulo, Brazil), analytical grade acetic acid 
from Mallinckrodt Baker and hydrochloric acid (HCl) 
were purchased from Merck (Darmstadt, Germany). 
Water was purified using a Millipore Direct-Q 3UV water 
purification system with pump (Millipore, Molsheim, 
France). A VAL stock solution of 1 mg.mL-1 was prepared 
in acetonitrile.
Acid stress condition
Studies of VAL degradation by acidic hydrolysis 
were carried out in 1 M HCl. For that, ca. 10 mg VAL 
were weighed and quantitatively transferred to a 50-mL 
two-neck round bottom flask and stirred with a magnetic 
bar with 50 mL of 1 M HCl. The acidic mixture was kept 
in the dark and under reflux at 358 K for 3 h. Samples 
were taken at 30-min intervals, neutralized and diluted 
with ammonium acetate buffer to 17 µg.mL-1 prior to 
HPLC analysis.
High Performance Liquid Chromatography (HPLC)
HPLC separations were performed using a Hypersil 
ODS (C18) column (250 x 4.6 mm i.d., 5 µm) at room 
temperature in both HPLC-PDA and HPLC-MS apparatuses. 
Isocratic elution was carried out at 1 mL.min-1with a mobile 
phase containing acetonitrile:water (45:55 v/v, 1.0% formic 
acid). The injection volume was 20 μL in both cases. The 
HPLC-PDA system was made up of an on-line degasser 
(DGU-20S5), a liquid chromatography apparatus (LC-
20AT), a communication bus module (CBM-20A), an auto 
sampler (SIL-20A), a column oven (CTO-10ASVP), a 
photodiode array (PDA) detector (SPD-M20A) with scan 
range of 190-800 nm and LC Solutions software version 
1.21 SP1 (Shimadzu, Kyoto, Japan).
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The HPLC-MS system was made up of an Alliance® 
HPLC separation module (Waters 2695) coupled to 
an electrospray (ESI) source and a QTrap 2000 mass 
spectrometer (Applied Biosystems/ABSciex). The ESI 
source temperature was 623 K and the transfer voltage 
was 4500 V. The ESI was operated in positive ion mode, 
viz. ESI (+).
ESI (+)- MS/MS analysis
To study the fragmentation of [VAL+H]+, a Q-TOF 
mass spectrometer (Micromass, Manchester, U.K.) was 
used for ESI(+)MS/MS analysis. Spectra were collected 
in the m/z range from 50 to 500. A formic acid aqueous 
solution was added to the sample mixture up to a total 
volume of 1,000 μL and a final concentration of 0.1% 
(v/v). Direct infusion was performed at a flow rate of 
10 μL min-1 via a syringe pump (Harvard Apparatus). High 
purity nitrogen at 1.5 L min-1 was used as a nebulizer as 
well as an auxiliary gas. The capillary and cone voltages 
were set at 3.0 kV and 35 V, respectively. Both the curved 
desolvation line (CDL) and heat block temperatures were 
maintained at 373 K. Collision-induced dissociation (CID) 
of the selected precursor ion was carried out with argon 
as the collision gas at a pressure optimized to produce 
extensive fragmentation of the ion under investigation.
RESULTS AND DISCUSSION
Degradation product monitoring
Forced acid degradation of VAL was monitored 
by HPLC-PDA. Figure 1 shows the representative 
HPLC-PDA chromatograms of VAL samples under acid 
stress condition taken at 30-min intervals.
The retention time of VAL was 10.7 min, which 
was confirmed by measurement of the drug standard 
FIGURE 1 - HPLC-PDA chromatogram for forced acid 
degradation of VAL in 1 M HCl under different stress conditions.
FIGURE 2 - Peak purity plot for forced acid degradation of VAL in 1 M at 30 min (A), 60 min (B), 120 min (C) and 180 min (D).
solution. No extra peak indicative of degradation was 
detected during exposure to 1 M HCl. Chromatographic 
data were also evaluated by asymmetric factor, theoretical 
plates and purity plot to identify the possible co-elution 
of degradation products. As shown in Figure 2, the VAL 
purity peak matches that of the VAL standard, showing 
no degradation over time. These results would induce the 
conclusion of high stability of VAL under exposure to 1 
M HCl up to 180 min. However, the asymmetric factor 
and theoretical plates varied slightly over time under acid 
stress condition, as shown in Table 1, indicating a possible 
co-elution of degradation products.
To confirm the HPLC-PDA results, the same 
samples were also analyzed by HPLC-MS. Figure 3 shows 
HPLC chromatograms obtained using ESI(+) and total ion 
current (TIC) monitoring, which sums up the intensity of 
all ions across the selected m/z range. Note that HPLC-
MS with TIC monitoring indicated no degradation either, 
likewise the HPLC-PDA results. A significance t-test was 
performed to compare the peak areas of the VAL standard 
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(n=3) and those in the chromatograms shown in Figure 1 
and Figure 2. The degree of freedom is 10; therefore, the 
critical value is t10=2.23 (P=0.05). The value obtained of 
t=1.89 is smaller than the critical value, thus, the variation 
in the VAL peak area is not significant when detected by 
PDA and MS.
Fortunately, however, the full ESI(+)-MS data 
was inspected, and as Figure 4 shows, at the VAL 
chromatographic peak at 10.7 min, the raising of two major 
ions of m/z 306 and 352 was detected, together with the 
ions from the parent drug, that is, m/z 436 for [M+H]+ and 
m/z 458 for [M+Na]+.
The ESI(+)-MS data unequivocally indicates 
that VAL indeed degraded to co-eluting products. The 
ions of m/z 306 and m/z 352, as well as that of VAL 
(m/z 436), were therefore recorded in the extracted ion 
chromatograms (XIC) (Figure 5). The XIC for the other 
minor ions observed in Figure 4 were also recorded and 
monitored as a function of the degradation time, but 
their profiles did not match those of the DP and were 
attributed to either VAL ion gas phase fragments or 
impurities.
Note the continuous increase in the DP relative 
abundance as a function of the exposure time with a 
corresponding and proportional decrease in the VAL 
concentration. Therefore, the selective HPLC-MS data 
provided actual evidence of extensive degradation of 
VAL under acid stress condition, whereas HPLC-PAD 
incorrectly indicated full stability. Figure 6 compares 
HPLC-MS monitoring via TIC and XIC of VAL 
degradation under acid stress condition. The ions of m/z 
306 and m/z 352 were thus attributed to the arising of VAL 
TABLE I - Asymmetry factor and theoretical plates of VAL at 
different times under acid stress condition
Time/min 0 30 60 120 180
Asa 1.3 1.4 1.2 1.5 1.8
Nb 1410 1385 1210 1180 1071
a Asymmetry factor; b Theoretical plates
FIGURE 3 - HPLC-MS chromatograms using ESI(+) and TIC 
for the acid stress degraded samples of VAL.
FIGURE 4 - Typical ESI(+) full mass spectrum for the VAL peak 
at RT = 10.7 min.
FIGURE 5 - HPLC-MS chromatograms using XIC monitoring for VAL degradation products: m/z 352 (A), m/z 306 (B) and 
[VAL+H]+ m/z 436 (C) in 1 M HCl for different exposure times.
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FIGURE 6 - VAL TIC and XIC HPLC-MS monitoring under 
acid stress degradation.
FIGURE 8 - ESI(+)-MSMS for the ions of a) m/z 436, b) 352 
and c) 306 obtained via direct infusion of VAL samples after 
180 min of exposure to acid stress condition.
DP protonated molecules by acid hydrolysis and Figure 7 
shows the proposed product structures.
ESI-MS/MS
Interestingly, the MS study of the fragmentation 
pattern of gaseous drugs in protonated, deprotonated 
and ionized forms has been found to match or provide 
insights on their degradation mechanisms and products 
(Amaral et al., 2011). The fragmentation patterns of 
gaseous molecules reveal the weaker molecule bonds; 
hence, some of the fragment ions may eventually match 
degradation products, particularly when the behavior of a 
protonated molecule is compared to that expected under 
acid stress condition. Figure 8 shows the ESI (+)-MS/
MS of [VAL+H]+ of m/z 436, as well as of the protonated 
molecules of its two major products of m/z 352 and m/z 
FIGURE 7 - VAL Degradation products as indicated by 
HPLC-MS monitoring.
306. Note that the fragments of [VAL+H]+ include the 
protonated molecules of m/z 352 and 306 of the detected 
DP (Scheme 1) (Mehta, Shah, Singh, 2010). The ESI 
(+)-MS/MS data for VAL and its DP may therefore 
include products that are likely to form under longer acid 
degradation.
CONCLUSION
HPLC-MS monitoring has shown that VAL 
degradation products under acid stress condition co-elute 
with the parent drug, resulting in misleading stability 
results when monitoring is performed through a less 
selective detection method such as HPLC-PAD. The 
high structural selectivity of HPLC-MS seems therefore 
required for comprehensive and effective studies of VAL 
degradation products and their formulations. Actually, 
HPLC-MS seems to be essential for drug degradation 
studies, particularly for new drugs and formulations, as 
well as for method development. Drug stability methods 
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developed through HPLC-UV or HPLC-PAD and so far 
exclusively monitored by either of these methods should 
therefore be co-validated by HPLC-MS in search for 
potential co-eluting degradation products.
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